VPS34-IN1 has been reported to inhibit tumor growth or cell survival in HCC [106], glioblastoma [113], and myeloid leukemia [130] when used alone and to synergize with ZSTK474 [106], vemurafenib [113], L-asparaginase [130], and ceritinib [11]. The gene discussed is PIK3C3; the disease is glioblastoma.